Recruiting

VT Ablation

Sponsor:

New York Medical College

Code:

NCT07814079

Conditions

Ventricular Tachycardia (VT)

Ischemic Cardiomyopathy

Nonischemic Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Selective Substrate Isolation

Study Details

Brief summary:

The goal of this study is to map conducting channels within scar that cause ventricular tachycardia (VT) in patients with scar in their hearts in order to block these channels from causing VT with targeted radiofrequency ablation (cautery).

Participants undergoing VT ablation mapping of these channels by pacing many sites within the scar area and determining where these channels exit the scar into normal tissue. These exits will be ablated. Immediate success and success at 1 year will be evaluated.

Conditions

Ventricular Tachycardia (VT)

Ischemic Cardiomyopathy

Nonischemic Cardiomyopathy

Study ID

NCT07814079

Start date

Mar 27, 2025

Status verified date

Aug, 2026

Completion date

Dec 9, 2028

Anticipated

Primary completion date

Dec 9, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with structural heart disease undergoing VT ablation

Exclusion Criteria:

1. Unable or unwilling to sign consent
2. Cardiogenic shock or NYHA Class IV heart failure and not a candidate for mechanical circulatory support for the procedure (percutaneous left ventricular assist device (LVAD), extracorporeal membrane oxygenation, or implanted LVAD)
3. Absence of substrate during initial voltage mapping

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Interventions

Selective Substrate Isolation

Ablation will be guided by mapping the substrate "from the inside out" by identifying conducting channels as they might be activated during VT. Extensive pace mapping will be performed within scar areas identified during sinus rhythm mapping. The course of these channels will be identified and ablated across the distal portion, just proximal to the exit based on shortest stimulus-to-QRS interval obtained.

Primary outcome measure

  • Number of participants achieving substrate Isolation with ablation of exit sites [ Time Frame: Perioperative/Periprocedural: This will be measured at the end of the study ablation procedure only. ]

Central Contacts and Locations

Locations

Westchester Medical Center

Recruiting

Valhalla, New York, United States, 10595

Contacts

Jason T Jacobson, MD

9144935314Jason.Jacobson@wmchealth.org

Sei Iwai, MD

9149096900Sei.Iwai@wmchealth.org

Principal Investigator:

Jason Jacobson, MD

More Information

Sponsor

New York Medical College

Last update posted

Sep 10, 2026

Last verified

Aug, 2026

Keywords

  • Ventricular tachycardia
  • substrate
  • mapping
  • reentry
  • cardiomyopathy
  • pacemapping

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-11. This information was provided to ClinicalTrials.gov by New York Medical College on 2026-09-10.